Abstract
Pharmacy acquisition costs for prescription (R
x
) drugs have been trending below levels implied by the Bureau of Labor Statistics’ (BLS) Consumer Price Index for R
x
drugs, with the divergence higher when generic approvals are high. Dropping the first 6 months of generic sales from price indices calculated from pharmacy acquisition costs eliminates most of the difference between such indices and BLS indices.
Read the full post on Wiley: Health Economics: Table of Contents
